Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in pcJIA (SKYPP)
NCT02776735Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2016
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of sarilumab in polyarticular juvenile idiopathic arthritis, sponsored by Sanofi. Started Sep 2016; status: completed.
02
Drugs
sarilumab
03
Conditions
polyarticular juvenile idiopathic arthritis
Beyond the preview
Go deeper on NCT02776735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776735.